Biological Treatments in Behçet’s Disease: Beyond Anti-TNF Therapy

Joint Authors

Caso, Paolo
Cantarini, Luca
Frediani, Bruno
Bascherini, Vittoria
Marrani, Edoardo
Nieves-Martín, Laura
Raffaele, Carmela G. L.
Tarantino, Giusyda
Atteno, Mariangela
Rigante, Donato
Punzi, Leonardo
Costa, Luisa
Caso, Francesco
Lucherini, Orso Maria
Cimaz, Rolando
Galeazzi, Mauro

Source

Mediators of Inflammation

Issue

Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-14, 14 p.

Publisher

Hindawi Publishing Corporation

Publication Date

2014-06-30

Country of Publication

Egypt

No. of Pages

14

Main Subjects

Diseases

Abstract EN

Behçet’s disease (BD) is universally recognized as a multisystemic inflammatory disease of unknown etiology with chronic course and unpredictable exacerbations: its clinical spectrum varies from pure vasculitic manifestations with thrombotic complications to protean inflammatory involvement of multiple organs and tissues.

Treatment has been revolutionized by the progressed knowledge in the pathogenetic mechanisms of BD, involving dysfunction and oversecretion of multiple proinflammatory molecules, chiefly tumor necrosis factor- (TNF-) α, interleukin- (IL-) 1β, and IL-6.

However, although biological treatment with anti-TNF-α agents has been largely demonstrated to be effective in BD, not all patients are definite responders, and this beneficial response might drop off over time.

Therefore, additional therapies for a subset of refractory patients with BD are inevitably needed.

Different agents targeting various cytokines and their receptors or cell surface molecules have been studied: the IL-1 receptor has been targeted by anakinra, the IL-1 by canakinumab and gevokizumab, the IL-6 receptor by tocilizumab, the IL12/23 receptor by ustekinumab, and the B-lymphocyte antigen CD-20 by rituximab.

The aim of this review is to summarize all current experiences and the most recent evidence regarding these novel approaches with biological drugs other than TNF-α blockers in BD, providing a valuable addition to the actually available therapeutic armamentarium.

American Psychological Association (APA)

Caso, Francesco& Costa, Luisa& Rigante, Donato& Lucherini, Orso Maria& Caso, Paolo& Bascherini, Vittoria…[et al.]. 2014. Biological Treatments in Behçet’s Disease: Beyond Anti-TNF Therapy. Mediators of Inflammation،Vol. 2014, no. 2014, pp.1-14.
https://search.emarefa.net/detail/BIM-1043311

Modern Language Association (MLA)

Caso, Francesco…[et al.]. Biological Treatments in Behçet’s Disease: Beyond Anti-TNF Therapy. Mediators of Inflammation No. 2014 (2014), pp.1-14.
https://search.emarefa.net/detail/BIM-1043311

American Medical Association (AMA)

Caso, Francesco& Costa, Luisa& Rigante, Donato& Lucherini, Orso Maria& Caso, Paolo& Bascherini, Vittoria…[et al.]. Biological Treatments in Behçet’s Disease: Beyond Anti-TNF Therapy. Mediators of Inflammation. 2014. Vol. 2014, no. 2014, pp.1-14.
https://search.emarefa.net/detail/BIM-1043311

Data Type

Journal Articles

Language

English

Notes

Includes bibliographical references

Record ID

BIM-1043311